Website
News25/Ratings1
News · 26 weeks22-33%
2025-10-262026-04-19
Mix790d
- Other3(43%)
- SEC Filings3(43%)
- Analyst1(14%)
Latest news
25 items- SECSEC Form PRER14A filed by Medicinova IncPRER14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form PRE 14A filed by Medicinova IncPRE 14A - MEDICINOVA INC (0001226616) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on MediciNova with a new price targetH.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00
- PRMediciNova to Participate at the 38th Annual ROTH ConferenceLA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. Drs. Iwaki and Crean will host one-on-one and small group meetings with investors and provide company updates. Investors interested in arranging a meeting should contact their representatives
- SECSEC Form 10-K filed by Medicinova Inc10-K - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsLA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: "Achieving 100 enrolled patients in the N
- INSIDERSEC Form 4 filed by Chief Medical Officer Matsuda Kazuko4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Iwaki Yuichi4 - MEDICINOVA INC (0001226616) (Issuer)
- PR2026 New Year's Greetings from the CEOLA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and persistent geopolitical risks. Despite these challenges, MediciNova achieved significant milestones, including completion of patient enrollment in three clinical trials and the launch of a large-
- SECSEC Form 424B5 filed by Medicinova Inc424B5 - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyLA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total
- SECSEC Form EFFECT filed by Medicinova IncEFFECT - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDLA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients' basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held December 5–7, 2025, in San Diego, California, USA. The poster presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics" (Reference # CTL-21),
- SECSEC Form S-3 filed by Medicinova IncS-3 - MEDICINOVA INC (0001226616) (Filer)
- PRMessage from the CEO to MediciNova ShareholdersLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages through upregulation of ABCA1 and ABCG1 transporters. This mechanism is critical because cholesterol efflux is the first step in Reverse Cholesterol Transport (RCT)—the body's natural process
- PRMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorLA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough AwardsLA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the "Contract Research and Development Innovation Award" at the Fifth Annual BioTech Breakthrough Awards. MediciNova earned this recognition for its innovative work advancing MN-166 (ibudilast), the company's lead small molecule drug candidate, currently in development for several neurological diseases, including amyotrophic lateral sclerosis (ALS), one of the fatal neurodegenerative diseases. MN-166 is designed t
- PRMediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (Tipelukast) for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). Patient recruitment is closed. The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001
- PRMediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed PublicationLA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and Thrombosis, the official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease. The study, titled, "Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis," is the result of a collaboration effort between MediciNova an
- PRMediciNova to Present at the LD Micro Main Event XIX Investor ConferenceLA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hotel Del Coronado in San Diego, CA. Presentation Date:Monday, October 20, 2025Time:1:30pm Pacific TimeRegister to view presentation:Webcast Link A live webcast of the presentation can be accessed on t
- SECSEC Form EFFECT filed by Medicinova IncEFFECT - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across two treatment arms at multiple clinical sites in the United States and Canada. Patient recruitment is now officially closed. MN-166 (ibudilast) is an orally administered small molecules designed to modulate neuroinflammation an